Tweet
Crit Pathw Cardiol. 2020 Apr 23. doi: 10.1097/HPC.0000000000000223. [Epub ahead of print]
Clinical Pathway for Management of Suspected or Positive Novel Coronavirus-19 Patients With ST-Segment Elevation Myocardial Infarction.
Ranard LS1, Ahmad Y1, Masoumi A1, Chuich T1, Romney MS2, Gavin N2, Sayan OR2, Kirtane AJ1, Rabbani LE1.
Author information
Abstract
Novel coronavirus-19 disease (COVID-19) is an escalating, highly infectious global pandemic that is quickly overwhelming healthcare systems. This has implications on standard cardiac care for ST-elevation myocardial infarctions (STEMIs). In the setting of anticipated resource scarcity in the future, we are forced to reconsider fibrinolytic therapy in our management algorithms. We encourage clinicians to maintain a high level of suspicion for STEMI mimics, such as myopericarditis which is a known, not infrequent, complication of COVID-19 disease. Herein, we present a pathway developed by a multidisciplinary panel of stakeholders at NewYork-Presbyterian/Columbia University Irving Medical Center for the management of STEMI in suspected or confirmed COVID-19 patients.
PMID:32356955DOI:10.1097/HPC.0000000000000223